title: Analysis of the anti-HIV-1 activity of an anti-p17-derivative peptide (P30-52) monoclonal antibody.
abstract: The object of this study was to examine the possibility of immunotherapy using anti-human immunodeficiency virus type 1 (HIV-1) p17-derivative peptide monoclonal antibody (MAb), namely MAb 8H10. Previously we established MAb 8H10, and further characterization revealed that it inhibited the viral multiplication of the HIV-1-infected MT-4 cells, and that the inhibitory mechanism related to the decrease of p17 DNA of the infected cells. In the present study, based on the assumption that Hybridoma 8H10 (Hyb 8H10) is a source of this MAb, we examined how Hyb 8H10 influences the infected cells when the two are co-cultured using the transwell or by mixed culture. Hyb 8H10 did not influence the cell growth or viability of MT-4 cells, and MAb 8H10 was transferred to the cluster dish containing the infected cells. Furthermore, Hyb 8H10 could produce MAb 8H10 even when co-cultured with the infected MT-4 cells. However, the infectivity of the supernatant of the infected cells was temporarily enhanced when Hyb 8H10 was co-cultured without MAb 8H10, though it gradually reduced according to the increase in MAb 8H10 produced by Hyb 8H10. Though there were some problems, MAb 8H10 proved to be a strong candidate for immunotherapy against HIV.
authors.affiliation: Department of Neurovirology, Research Institute for Microbial Diseases, Osaka University, Japan.
authors.forename: A
authors.initials: A
authors.lastname: Ota
authors.forename: S
authors.initials: S
authors.lastname: Ueda
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D000918:Antibody Specificity; D002455:Cell Division / Q000187:drug effects; D018920:Coculture Techniques; D004279:DNA, Viral / Q000032:analysis / Q000096:biosynthesis / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D015683:Gene Products, gag / Q000138:chemical synthesis / Q000235:genetics / Q000276:immunology*; D015483:HIV Antibodies / Q000276:immunology* / Q000494:pharmacology*; D015488:HIV Antigens / Q000235:genetics / Q000276:immunology*; D015497:HIV-1 / Q000235:genetics / Q000276:immunology / Q000502:physiology*; D006801:Humans; D006825:Hybridomas / Q000276:immunology / Q000821:virology; D051379:Mice; D010446:Peptide Fragments / Q000138:chemical synthesis / Q000276:immunology; D013997:Time Factors; D014407:Tumor Cells, Cultured / Q000737:chemistry / Q000276:immunology / Q000821:virology; D014764:Viral Proteins; D014779:Virus Replication / Q000187:drug effects; D054301:gag Gene Products, Human Immunodeficiency Virus
chemical_list: D000911:Antibodies, Monoclonal; D004279:DNA, Viral; D015683:Gene Products, gag; D015483:HIV Antibodies; D015488:HIV Antigens; D010446:Peptide Fragments; D014764:Viral Proteins; D054301:gag Gene Products, Human Immunodeficiency Virus; C054858:p17 protein, Human Immunodeficiency Virus Type 1